Case Report: Immune-directed post-transplant maintenance with low-dose gemtuzumab ozogamicin and stepwise donor lymphocyte infusion in acute myeloid leukemia with t(1;3)(p36.3;q21).
- DOI
- 10.3389/fimmu.2026.1888993
- Published
- 2026
- Container
- Frontiers in immunology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1888993,
title = {Case Report: Immune-directed post-transplant maintenance with low-dose gemtuzumab ozogamicin and stepwise donor lymphocyte infusion in acute myeloid leukemia with t(1;3)(p36.3;q21).},
author = {Ouchi F and Najima Y and Haraguchi K and Sadato D and Hirama C and Morita K and Toya T and Shimizu H and Toubai T and Harada H and Harada Y and Doki N},
year = {2026},
journal = {Frontiers in immunology},
doi = {10.3389/fimmu.2026.1888993},
url = {https://doi.org/10.3389/fimmu.2026.1888993}
}RIS
TY - JOUR TI - Case Report: Immune-directed post-transplant maintenance with low-dose gemtuzumab ozogamicin and stepwise donor lymphocyte infusion in acute myeloid leukemia with t(1;3)(p36.3;q21). AU - Ouchi F AU - Najima Y AU - Haraguchi K AU - Sadato D AU - Hirama C AU - Morita K AU - Toya T AU - Shimizu H AU - Toubai T AU - Harada H AU - Harada Y AU - Doki N PY - 2026 JO - Frontiers in immunology DO - 10.3389/fimmu.2026.1888993 UR - https://doi.org/10.3389/fimmu.2026.1888993 ER -
APA
F, O., Y, N., K, H., D, S., C, H., K, M., T, T., H, S., T, T., H, H., Y, H., & N, D. (2026). Case Report: Immune-directed post-transplant maintenance with low-dose gemtuzumab ozogamicin and stepwise donor lymphocyte infusion in acute myeloid leukemia with t(1;3)(p36.3;q21).. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1888993
Source records
- pubmed · retrieved 2026-11-10T11:39:17.708Z